Epidemiology and management of Buruli ulcer

References

• MacCallum P, Tolhurst JC, Buckle G, Sissons H. A new mycobacterial infection in man. J Pathol Bacteriol 1948;60(1):93-122
   PubMedGoogle Scholar
• Johnson PD, Stinear T, Small PL, et al. Buruli ulcer (M. ulcerans infection): new insights, new hope for disease control. PLoS Med 2005;2(4):e108
   PubMed Web of Science ®Google Scholar
• Clancey J, Dodge R, Lunn HF. Study of a mycobacterium causing skin ulceration in Uganda. Ann Soc Belg Med Trop 1962;42:585-90
   Google Scholar
• Debacker M, Portaels F, Aguiar J, et al. Risk factors for Buruli ulcer, Benin. Emerg Infect Dis 2006;12(9):1325-31
   PubMed Web of Science ®Google Scholar
• Jenkins GA, Smith M, Fairley M, Johnson PD. Acute, oedematous Mycobacterium ulcerans infection in a farmer from far north Queensland. Med J Aust 2002;176(4):180-1
   PubMed Web of Science ®Google Scholar
• Trevillyan JM, Johnson PD. Steroids control paradoxical worsening of Mycobacterium ulcerans infection following initiation of antibiotic therapy. Med J Aust 2013;198(8):443-4
   PubMed Web of Science ®Google Scholar
• O’Brien DP, Friedman ND, McDonald A, et al. Clinical features and risk factors of oedematous Mycobacterium ulcerans lesions in an Australian population: beware cellulitis in an endemic area. PLoS Negl Trop Dis 2014;8(1):e2612
   PubMed Web of Science ®Google Scholar
• Bayonne Manou LS, Portaels F, Eddyani M, et al. Mycobacterium ulcerans disease (Buruli ulcer) in Gabon: 2005-2011. Med Sante Trop 2013;23(4):450-7
   PubMedGoogle Scholar
• Stienstra Y, van der Graaf WT, Asamoa K, van der Werf TS. Beliefs and attitudes toward Buruli ulcer in Ghana. Am J Trop Med Hyg 2002;67(2):207-13
   PubMed Web of Science ®Google Scholar
• Debacker M, Aguiar J, Steunou C, et al. Mycobacterium ulcerans disease (Buruli ulcer) in rural hospital, Southern Benin, 1997-2001. Emerg Infect Dis 2004;10(8):1391-8
   PubMed Web of Science ®Google Scholar
• Aujoulat I, Johnson C, Zinsou C, et al. Psychosocial aspects of health seeking behaviours of patients with Buruli ulcer in southern Benin. Trop Med Int Health 2003;8(8):750-9
   PubMed Web of Science ®Google Scholar
• Gordon CL, Buntine JA, Hayman JA, et al. Spontaneous clearance of Mycobacterium ulcerans in a case of Buruli ulcer. PLoS Negl Trop Dis 2011;5(10):e1290
   PubMed Web of Science ®Google Scholar
• World Health Organization. The 17 neglected tropical diseases. Available from: www.who.int/neglected_diseases/diseases/en/ [Last accessed 7 February 2014]
   Google Scholar
• World Health Organization (2012). Treatment of Mycobacterium Ulcerans Disease (Buruli Ulcer). WHO/HTM/NTD/IDM/2012.1. Available from: http://apps.who.int/iris/bitstream/10665/77771/1/9789241503402_eng.pdf [Last accessed 10 February 2014]
   Google Scholar
• Quek TY, Athan E, Henry MJ, et al. Risk factors for Mycobacterium ulcerans infection, Southeastern Australia. Emerg Infect Dis 2007;13(11):1661-6
   PubMed Web of Science ®Google Scholar
• Stinear TP, Seemann T, Pidot S, et al. Reductive evolution and niche adaptation inferred from the genome of Mycobacterium ulcerans, the causative agent of Buruli ulcer. Genome Res 2007;17(2):192-200
   PubMed Web of Science ®Google Scholar
• Stinear TP, Seemann T, Harrison PF, et al. Insights from the complete genome sequence of Mycobacterium marinum on the evolution of Mycobacterium tuberculosis. Genome Res 2008;18(5):729-41
   PubMed Web of Science ®Google Scholar
• Hayman J, McQueen A. The pathology of Mycobacterium ulcerans infection. Pathology 1985;17(4):594-600
   PubMed Web of Science ®Google Scholar
• Ruf MT, Sopoh GE, Brun LV, et al. Histopathological changes and clinical responses of Buruli ulcer plaque lesions during chemotherapy: a role for surgical removal of necrotic tissue? PLoS Negl Trop Dis 2011;5(9):e1334
   PubMed Web of Science ®Google Scholar
• Schutte D, Umboock A, Pluschke G. Phagocytosis of Mycobacterium ulcerans in the course of rifampicin and streptomycin chemotherapy in Buruli ulcer lesions. Br J Dermatol 2009;160(2):273-83
   PubMed Web of Science ®Google Scholar
• Stinear TP, Mve-Obiang A, Small PL, et al. Giant plasmid-encoded polyketide synthases produce the macrolide toxin of Mycobacterium ulcerans. Proc Natl Acad Sci USA 2004;101(5):1345-9
   PubMed Web of Science ®Google Scholar
• George KM, Chatterjee D, Gunawardana G, et al. Mycolactone: a polyketide toxin from Mycobacterium ulcerans required for virulence. Science 1999;283(5403):854-7
   PubMed Web of Science ®Google Scholar
• George KM, Pascopella L, Welty DM, Small PL. A Mycobacterium ulcerans toxin, mycolactone, causes apoptosis in guinea pig ulcers and tissue culture cells. Infect Immun 2000;68(2):877-83
   PubMed Web of Science ®Google Scholar
• Ross BC, Marino L, Oppedisano F, et al. Development of a PCR assay for rapid diagnosis of Mycobacterium ulcerans infection. J Clin Microbiol 1997;35(7):1696-700
   PubMed Web of Science ®Google Scholar
• Eddyani M, Fraga AG, Schmitt F, et al. Fine-needle aspiration, an efficient sampling technique for bacteriological diagnosis of nonulcerative Buruli ulcer. J Clin Microbiol 2009;47(6):1700-4
   PubMed Web of Science ®Google Scholar
• Portaels F, Johnson P, Meyers WM. Buruli ulcer: Diagnosis of Mycobacterium ulcerans disease. Geneva: World Health Organization (2001). Available from: https://extranet.who.int/iris/restricted/handle/10665/67000 [Last accessed 7 February 2014]
   Google Scholar
• Eddyani M, Portaels F. Survival of Mycobacterium ulcerans at 37 degrees C. Clin Microbiol Infect 2007;13(10):1033-5
   PubMed Web of Science ®Google Scholar
• WHO(2013). Buruli ulcer (Mycobacterium ucerans infection) Fact sheet N°199. Available from: www.who.int/mediacentre/factsheets/fs199/en/ [Last accessed 19 March 2014]
   Google Scholar
• World Health Organization (2012). Number of new cases of Buruli ulcer reported, 2012. Available from: http://apps.who.int/neglected_disease/ntddata/buruli/buruli.html [Last accessed 19 March 2014]
   Google Scholar
• Communicable Diseases Epidemiology and Surveillance Health Protection Branch – Department of Health, Victoria, Australia. Surveillance of notifiable conditions in Victoria, Victorian summary report – 1 January to 12 February 2014. Available from: www.health.vic.gov.au/ideas/downloads/daily_reports/rptVS_SNIDSVictorianSummary_GR.pdf [Last accessed 17 February 2014]
   Google Scholar
• Carson C, Lavender CJ, Handasyde KA, et al. Potential wildlife sentinels for monitoring the endemic spread of human buruli ulcer in South-East australia. PLoS Negl Trop Dis 2014;8(1):e2668
   PubMed Web of Science ®Google Scholar
• Trubiano JA, Lavender CJ, Fyfe JA, et al. The incubation period of Buruli ulcer (Mycobacterium ulcerans infection). PLoS Negl Trop Dis 2013;7(10):e2463
   PubMed Web of Science ®Google Scholar
• Smith M. Studies on Mycobacterium ulcerans infection in the Douglas Shire of far-north Queensland, Australia. Thesis; Faculty of Tropical Veterinary Science and Agriculture. James Cook University; Townsville, Australia: 1996
   Google Scholar
• Johnson PD, Azuolas J, Lavender CJ, et al. Mycobacterium ulcerans in mosquitoes captured during outbreak of Buruli ulcer, southeastern Australia. Emerg Infect Dis 2007;13(11):1653-60
   PubMed Web of Science ®Google Scholar
• Merritt RW, Walker ED, Small PL, et al. Ecology and transmission of Buruli ulcer disease: a systematic review. PLoS Negl Trop Dis 2010;4(12):e911
   PubMed Web of Science ®Google Scholar
• Jacobsen KH, Padgett JJ. Risk factors for Mycobacterium ulcerans infection. Int J Infect Dis 2010;14(8):e677-81
   PubMed Web of Science ®Google Scholar
• Hayman J. Postulated epidemiology of Mycobacterium ulcerans infection. Int J Epidemiol 1991;20(4):1093-8
   PubMed Web of Science ®Google Scholar
• Veitch MG, Johnson PD, Flood PE, et al. A large localized outbreak of Mycobacterium ulcerans infection on a temperate southern Australian island. Epidemiol Infect 1997;119(3):313-18
   PubMed Web of Science ®Google Scholar
• Marsollier L, Robert R, Aubry J, et al. Aquatic insects as a vector for Mycobacterium ulcerans. Appl Environ Microbiol 2002;68(9):4623-8
   PubMed Web of Science ®Google Scholar
• Portaels F, Elsen P, Guimaraes-Peres A, et al. Insects in the transmission of Mycobacterium ulcerans infection. Lancet 1999;353(9157):986
   PubMed Web of Science ®Google Scholar
• Portaels F, Meyers WM, Ablordey A, et al. First cultivation and characterization of Mycobacterium ulcerans from the environment. PLoS Negl Trop Dis 2008;2(3):e178
   PubMed Web of Science ®Google Scholar
• Benbow ME, Williamson H, Kimbirauskas R, et al. Aquatic invertebrates as unlikely vectors of Buruli ulcer disease. Emerg Infect Dis 2008;14(8):1247-54
   PubMed Web of Science ®Google Scholar
• The Uganda Buruli Group. Epidemiology of Mycobacterium ulcerans infection (Buruli ulcer) at Kinyara, Uganda. Trans R Soc Trop Med Hyg 1971;65(6):763-75
   PubMed Web of Science ®Google Scholar
• O’Brien CR, Handasyde KA, Hibble J, et al. Clinical, Microbiological and Pathological Findings of Mycobacterium ulcerans Infection in Three Australian Possum Species. PLoS Negl Trop Dis 2014;8(1):e2666
   PubMed Web of Science ®Google Scholar
• Sarfo FS, Lavender CJ, Fyfe JA, et al. Mycobacterium ulcerans DNA not detected in faecal samples from Buruli ulcer patients: results of a pilot study. PLoS One 2011;6(5):e19611
   PubMed Web of Science ®Google Scholar
• Fyfe JA, Lavender CJ, Handasyde KA, et al. A major role for mammals in the ecology of Mycobacterium ulcerans. PLoS Negl Trop Dis 2010;4(8):e791
   PubMed Web of Science ®Google Scholar
• Lavender CJ, Fyfe JA, Azuolas J, et al. Risk of Buruli ulcer and detection of Mycobacterium ulcerans in mosquitoes in southeastern Australia. PLoS Negl Trop Dis 2011;5(9):e1305
   PubMed Web of Science ®Google Scholar
• Bratschi MW, Bolz M, Minyem JC, et al. Geographic distribution, age pattern and sites of lesions in a cohort of Buruli ulcer patients from the Mape Basin of Cameroon. PLoS Negl Trop Dis 2013;7(6):e2252
   PubMed Web of Science ®Google Scholar
• Debacker M, Aguiar J, Steunou C, et al. Buruli ulcer recurrence, Benin. Emerg Infect Dis 2005;11(4):584-9
   PubMed Web of Science ®Google Scholar
• van der Werf TS, van der Graaf WT, Tappero JW, Asiedu K. Mycobacterium ulcerans infection. Lancet 1999;354(9183):1013-18
   PubMed Web of Science ®Google Scholar
• Teelken MA, Stienstra Y, Ellen DE, et al. Buruli ulcer: differences in treatment outcome between two centres in Ghana. Acta Trop 2003;88(1):51-6
   PubMed Web of Science ®Google Scholar
• O’Brien DP, Walton A, Hughes AJ, et al. Risk factors for recurrent Mycobacterium ulcerans disease after exclusive surgical treatment in an Australian cohort. Med J Aust 2013;198(8):436-9
   PubMed Web of Science ®Google Scholar
• Revill WD, Morrow RH, Pike MC, Ateng J. A controlled trial of the treatment of Mycobacterium ulcerans infection with clofazimine. Lancet 1973;2(7834):873-7
   PubMed Web of Science ®Google Scholar
• Fehr H, Egger M, Senn I. Cotrimoxazol in the treatment of Mycobacterium ulcerans infection (Buruli ulcer) in west Africa. Trop Doct 1994;24(2):61-3
   PubMed Web of Science ®Google Scholar
• Espey DK, Djomand G, Diomande I, et al. A pilot study of treatment of Buruli ulcer with rifampin and dapsone. Int J Infect Dis 2002;6(1):60-5
   PubMedGoogle Scholar
• Thangaraj HS, Adjei O, Allen BW, et al. In vitro activity of ciprofloxacin, sparfloxacin, ofloxacin, amikacin and rifampicin against Ghanaian isolates of Mycobacterium ulcerans. J Antimicrob Chemother 2000;45(2):231-3
   PubMed Web of Science ®Google Scholar
• Portaels F, Traore H, De Ridder K, Meyers WM. In vitro susceptibility of Mycobacterium ulcerans to clarithromycin. Antimicrob Agents Chemother 1998;42(8):2070-3
   PubMed Web of Science ®Google Scholar
• Marsollier L, Prevot G, Honore N, et al. Susceptibility of Mycobacterium ulcerans to a combination of amikacin/rifampicin. Int J Antimicrob Agents 2003;22(6):562-6
   PubMed Web of Science ®Google Scholar
• Etuaful S, Carbonnelle B, Grosset J, et al. Efficacy of the combination rifampin-streptomycin in preventing growth of Mycobacterium ulcerans in early lesions of Buruli ulcer in humans. Antimicrob Agents Chemother 2005;49(8):3182-6
   PubMed Web of Science ®Google Scholar
• World Health Organization 2004. Provisional guidance on the role of specific antibiotics in the management of Mycobacterium ulcerans disease (Buruli ulcer). WHO/CDS/CPE/GBUI/2004.10. Available from: www.who.int/buruli/information/publications/Provisional_guidance.pdf [Last accessed 8 February 2014]
   Google Scholar
• Chauty A, Ardant MF, Adeye A, et al. Promising clinical efficacy of streptomycin-rifampin combination for treatment of buruli ulcer (Mycobacterium ulcerans disease). Antimicrob Agents Chemother 2007;51(11):4029-35
   PubMed Web of Science ®Google Scholar
• Sarfo FS, Phillips R, Asiedu K, et al. Clinical efficacy of combination of rifampin and streptomycin for treatment of Mycobacterium ulcerans disease. Antimicrob Agents Chemother 2010;54(9):3678-85
   PubMed Web of Science ®Google Scholar
• Kibadi K, Boelaert M, Fraga AG, et al. Response to treatment in a prospective cohort of patients with large ulcerated lesions suspected to be Buruli Ulcer (Mycobacterium ulcerans disease). PLoS Negl Trop Dis 2010;4(7):e736
   PubMed Web of Science ®Google Scholar
• Johnson PD, Hayman JA, Quek TY, et al. Consensus recommendations for the diagnosis, treatment and control of Mycobacterium ulcerans infection (Bairnsdale or Buruli ulcer) in Victoria, Australia. Med J Aust 2007;186(2):64-8
   PubMed Web of Science ®Google Scholar
• O’Brien DP, Jenkin G, Buntine J, et al. Treatment and prevention of mycobacterium ulcerans infection (Buruli ulcer) in Australia: guideline update. Med J Aust 2014;200(5):267-70
   PubMed Web of Science ®Google Scholar
• Steffen CM, Smith M, McBride WJ. Mycobacterium ulcerans infection in North Queensland: the ’Daintree ulcer’. ANZ J Surg 2010;80(10):732-6
   PubMed Web of Science ®Google Scholar
• Steffen CM. Risk factors for recurrent Mycobacterium ulcerans disease after exclusive surgical treatment in an Australian cohort. Med J Aust 2014;200(2):85-6
   PubMed Web of Science ®Google Scholar
• O’Brien DP, Hughes AJ, Cheng AC, et al. Outcomes for Mycobacterium ulcerans infection with combined surgery and antibiotic therapy: findings from a south-eastern Australian case series. Med J Aust 2007;186(2):58-61
   PubMed Web of Science ®Google Scholar
• Dossou AD, Sopoh GE, Johnson CR, et al. Management of Mycobacterium ulcerans infection in a pregnant woman in Benin using rifampicin and clarithromycin. Med J Aust 2008;189(9):532-3
   PubMed Web of Science ®Google Scholar
• Gordon CL, Buntine JA, Hayman JA, et al. All-oral antibiotic treatment for buruli ulcer: a report of four patients. PLoS Negl Trop Dis 2010;4(11):e770
   PubMed Web of Science ®Google Scholar
• Nienhuis WA, Stienstra Y, Thompson WA, et al. Antimicrobial treatment for early, limited Mycobacterium ulcerans infection: a randomised controlled trial. Lancet 2010;375(9715):664-72
   PubMed Web of Science ®Google Scholar
• Phillips RO, Sarfo FS, Abass MK, et al. Clinical and bacteriological efficacy of rifampin-streptomycin combination for two weeks followed by rifampin and clarithromycin for six weeks for treatment of Mycobacterium ulcerans disease. Antimicrob Agents Chemother 2014;58(2):1161-6
   PubMed Web of Science ®Google Scholar
• Chauty A, Ardant MF, Marsollier L, et al. Oral treatment for Mycobacterium ulcerans infection: results from a pilot study in Benin. Clin Infect Dis 2011;52(1):94-6
   PubMed Web of Science ®Google Scholar
• O’Brien DP, McDonald A, Callan P, et al. Successful outcomes with oral fluoroquinolones combined with rifampicin in the treatment of Mycobacterium ulcerans: an observational cohort study. PLoS Negl Trop Dis 2012;6(1):e1473
   PubMed Web of Science ®Google Scholar
• Friedman ND, Athan E, Hughes AJ, et al. Mycobacterium ulcerans disease: experience with primary oral medical therapy in an Australian cohort. PLoS Negl Trop Dis 2013;7(7):e2315
   PubMed Web of Science ®Google Scholar
• Ji B, Chauffour A, Robert J, et al. Orally administered combined regimens for treatment of Mycobacterium ulcerans infection in mice. Antimicrob Agents Chemother 2007;51(10):3737-9
   PubMed Web of Science ®Google Scholar
• Nienhuis WA, Stienstra Y, Abass KM, et al. Paradoxical responses after start of antimicrobial treatment in Mycobacterium ulcerans infection. Clin Infect Dis 2012;54(4):519-26
   PubMed Web of Science ®Google Scholar
• Simonet V. Prevention of disability in Buruli ulcer: basic rehabilitation. A practical field guide. Geneva, World Health Organization, 2008. Available from: http://whqlibdoc.who.int/hq/2008/WHO_HTM_NTD_IDM_GBUI_2008.1_eng.pdf [Last accessed 10 February 2014]
   Google Scholar
• O’Brien DP, Robson ME, Callan PP, McDonald AH. “Paradoxical” immune-mediated reactions to Mycobacterium ulcerans during antibiotic treatment: a result of treatment success, not failure. Med J Aust 2009;191(10):564-6
   PubMed Web of Science ®Google Scholar
• Carvalho AC, De Iaco G, Saleri N, et al. Paradoxical reaction during tuberculosis treatment in HIV-seronegative patients. Clin Infect Dis 2006;42(6):893-5
   PubMed Web of Science ®Google Scholar
• Breen RA, Smith CJ, Bettinson H, et al. Paradoxical reactions during tuberculosis treatment in patients with and without HIV co-infection. Thorax 2004;59(8):704-7
   PubMed Web of Science ®Google Scholar
• O’Brien DP, Robson M, Friedman ND, et al. Incidence, clinical spectrum, diagnostic features, treatment and predictors of paradoxical reactions during antibiotic treatment of Mycobacterium ulcerans infections. BMC Infect Dis 2013;13(1):416
   PubMedGoogle Scholar
• Meintjes G, Wilkinson RJ, Morroni C, et al. Randomized placebo-controlled trial of prednisone for paradoxical tuberculosis-associated immune reconstitution inflammatory syndrome. AIDS 2010;24(15):2381-90
   PubMed Web of Science ®Google Scholar
• Friedman ND, McDonald AH, Robson ME, O’Brien DP. Corticosteroid use for paradoxical reactions during antibiotic treatment for Mycobacterium ulcerans. PLoS Negl Trop Dis 2012;6(9):e1767
   PubMed Web of Science ®Google Scholar
• Johnson RC, Nackers F, Glynn JR, et al. Association of HIV infection and Mycobacterium ulcerans disease in Benin. AIDS 2008;22(7):901-3
   PubMed Web of Science ®Google Scholar
• Christinet V. Collaboration between HUG and MSF: the HIV-Buruli project at Akonolinga, Cameroon. In: WHO Annual Meeting on Buruli Ulcer; 22-24 March 2010; World Health Organization, Geneva, Switzerland
   Google Scholar
• Johnson RC, Ifebe D, Hans-Moevi A, et al. Disseminated Mycobacterium ulcerans disease in an HIV-positive patient: a case study. AIDS 2002;16(12):1704-5
   PubMedGoogle Scholar
• Toll A, Gallardo F, Ferran M, et al. Aggressive multifocal Buruli ulcer with associated osteomyelitis in an HIV-positive patient. Clin Exp Dermatol 2005;30(6):649-51
   PubMed Web of Science ®Google Scholar
• Meyers WM, Shelly WM, Connor DH. Heat treatment of Mycobacterium ulcerans infections without surgical excision. Am J Trop Med Hyg 1974;23(5):924-9
   PubMed Web of Science ®Google Scholar
• Junghanss T, Um Boock A, Vogel M, et al. Phase change material for thermotherapy of Buruli ulcer: a prospective observational single centre proof-of-principle trial. PLoS Negl Trop Dis 2009;3(2):e380
   PubMed Web of Science ®Google Scholar
• Trigo G, Martins TG, Fraga AG, et al. Phage therapy is effective against infection by Mycobacterium ulcerans in a murine footpad model. PLoS Negl Trop Dis 2013;7(4):e2183
   PubMed Web of Science ®Google Scholar